Initial assessment of the role of CXC chemokine receptor 4 after polytrauma.
CXC chemokine receptor (CXCR)-4 agonists have been shown to attenuate inflammation and organ injury in various disease models, including trauma/hemorrhage. The pathophysiological role of CXCR4 during the early response to tissue injury, however, remains unknown. Therefore, we investigated the effects of AMD3100, a drug that antagonizes binding of stromal cell-derived factor (SDF)-1α and ubiquitin to CXCR4 during the initial response to polytrauma in pigs. Fifteen minutes before polytrauma (femur fractures/lung contusion; control: sham), 350 nmol/kg AMD3100, equimolar AMD3100 and ubiquitin (350 nmol/kg each) or vehicle were administered intravenously. After a 60-min shock period, fluid resuscitation was performed for 360 min. Ubiquitin binding to peripheral blood mononuclear cells was significantly reduced after intravenous AMD3100. SDF-1α plasma levels increased transiently >10-fold with AMD3100 in all animals. In injured animals, AMD3100 increased fluid requirements to maintain hemodynamics and enhanced increases in peripheral blood granulocytes, lymphocytes and monocytes, compared with its effects in uninjured animals. Cytokine release from leukocytes in response to Toll-like receptor (TLR)-2 and TLR-4 activation was increased after in vitro AMD3100 treatment of normal whole blood and after in vivo AMD3100 administration in animals subjected to polytrauma. Coadministration of AMD3100/ubiquitin reduced lactate levels, prevented AMD3100-induced increases in fluid requirements and sensitization of the tumor necrosis factor (TNF)-α and interleukin (IL)-6 release upon TLR-2/4 activation, but did not attenuate increases in leukocyte counts and SDF-1α plasma levels. Our findings suggest that CXCR4 controls leukocyte mobilization after trauma, regulates leukocyte reactivity toward inflammatory stimuli and mediates protective effects during the early phase of trauma-induced inflammation.
Department of Surgery, Burn and Shock Trauma Institute, Loyola University Chicago, Maywood, Illinois, United States of America.
Harold H
HH
Bach
Vikas
V
Saini
Todd A
TA
Baker
Abhishek
A
Tripathi
Richard L
RL
Gamelli
Matthias
M
Majetschak
D000818:Animals; D001596:Benzylamines; D000080027:Cyclams; D005260:Female; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology; D015850:Interleukin-6 / Q000378:metabolism; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D011485:Protein Binding / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000378:metabolism; D034421:Sus scrofa; D013682:Teichoic Acids / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D025801:Ubiquitin / Q000378:metabolism; D014947:Wounds and Injuries / Q000097:blood / Q000378:metabolism*
D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D015850:Interleukin-6; D008070:Lipopolysaccharides; D019718:Receptors, CXCR4; D011956:Receptors, Cell Surface; D013682:Teichoic Acids; D014409:Tumor Necrosis Factor-alpha; D025801:Ubiquitin; C009900:lipoteichoic acid; C088327:plerixafor